Gemcitabine: defining the future of ovarian cancer therapyOZOLS, Robert F.Seminars in oncology. 2002, Vol 29, Num 1, issn 0093-7754, 43 p., SUP1Serial Issue

Surgical management of ovarian cancerMUTCH, David G.Seminars in oncology. 2002, Vol 29, Num 1, pp 3-8, issn 0093-7754, SUP1Article

The role of gemcitabine-based doublets in the management of ovarian carcinomaTHIGPEN, Tate.Seminars in oncology. 2002, Vol 29, Num 1, pp 11-16, issn 0093-7754, SUP1Article

Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinomaHANSEN, Steen Werner.Seminars in oncology. 2002, Vol 29, Num 1, pp 17-19, issn 0093-7754, SUP1Article

Second-line treatment of ovarian cancer with single-agent gemcitabineMARKMAN, Maurie.Seminars in oncology. 2002, Vol 29, Num 1, pp 9-10, issn 0093-7754, SUP1Article

Future directions in the treatment of ovarian cancerOZOLS, Robert F.Seminars in oncology. 2002, Vol 29, Num 1, pp 32-42, issn 0093-7754, SUP1Article

Developmental chemotherapy in advanced ovarian cancer: Incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182)BOOKMAN, Michael A.Seminars in oncology. 2002, Vol 29, Num 1, pp 20-31, issn 0093-7754, SUP1Article